Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Andrew Kent, MD PhD, Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138832

Published: 2020

Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-136120

Published: 2020

Journal Articles

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138821

Published: 2020

Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Blood (2019) 134 (Supplement_1): 185.

https://doi.org/10.1182/blood-2019-131390

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Justin D. Kaner, MD, Montreh Tavakkoli, MA,MD, Lisa Toudic, Brett M. Stevens, PhD, Craig T Jordan, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Ellen K. Ritchie, MD, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Sangmin Lee, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 3935.

https://doi.org/10.1182/blood-2019-128276

Published: 2019

Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Blood (2019) 134 (Supplement_1): 2638.

https://doi.org/10.1182/blood-2019-122120

Published: 2019

Journal Articles

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

James Chavez, BS, Jennifer L Rabe, BS, BA, Kelly Higa, MS, Dirk Loeffler, Ahmed Nouraiz, PhD, Taylor Mills, BA, Beau M Idler, Brett M. Stevens, PhD, Courtney Fleenor, PhD, Claus Nerlov, PhD, Hideaki Nakajima, MD, James Hagman, Timm Schroeder, PhD, Hyun Min Kim, PhD, Craig T Jordan, PhD, James DeGregori, Eric Pietras, PhD

Blood (2019) 134 (Supplement_1): 822.

https://doi.org/10.1182/blood-2019-129300

Published: 2019

Journal Articles

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

Courtney L Jones, PhD, Brett M. Stevens, PhD, Rachel Culp-Hill, BS, Angelo Dalessandro, PhD, Anna Krug, BS, Madeline Goosman, Shanshan Pei, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2019) 134 (Supplement_1): 1272.

https://doi.org/10.1182/blood-2019-125773

Published: 2019

Journal Articles

STAT3 Plays a Critical Role in Mitochondrial Function and Survival of Primary AML Cells

Maria L Amaya, MD PhD, Anagha Inguva, BSc, Courtney L Jones, PhD, Anna Krug, BS, Shanshan Pei, PhD, Phillip Reigan, PhD, Craig T Jordan, PhD

Blood (2019) 134 (Supplement_1): 1275.

https://doi.org/10.1182/blood-2019-127669

Published: 2019

Journal Articles

Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality

Blood (2018) 132 (Supplement 1): 2573.

https://doi.org/10.1182/blood-2018-99-120272

Published: 2018

Journal Articles

Subversion of Systemic Glucose Metabolism As a Mechanism to Support the Growth of Leukemia Cells

Haobin Ye, PhD, Biniam Adane, PhD, Nabilah Khan, Mohd Minhajuddin, PhD, Brett M. Stevens, PhDBS, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 908.

https://doi.org/10.1182/blood-2018-99-117064

Published: 2018

Journal Articles

PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia

Brett M. Stevens, PhDBS, Courtney L Jones, PhD, Amanda Winters, MDPhD, James Dugan, MD, Diana Abbott, PhD, Michael R. Savona, MD, Stephen W. Fesik, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 909.

https://doi.org/10.1182/blood-2018-99-119806

Published: 2018

Journal Articles

Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism

Courtney L Jones, PhD, Brett M Stevens, PhD, Rachel Culp-Hill, BS, Travis Nemkov, Angelo D'Alessandro, PhD, Shanshan Pei, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 429.

https://doi.org/10.1182/blood-2018-99-111366

Published: 2018

Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 432.

https://doi.org/10.1182/blood-2018-99-111507

Published: 2018

Journal Articles

Cysteine and Cystine Depletion Targets Leukemia Stem Cells

Courtney L Jones, PhD, Brett M Stevens, PhD, Angelo D'Alessandro, Rachel Culp-Hill, BS, Julie Reisz, PhD, Haobin Ye, PhD, Nabilah Khan, Mohd Minhajuddin, PhD, James DeGregori, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 431.

https://doi.org/10.1182/blood-2018-99-113181

Published: 2018

Journal Articles

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Zachary J Walker, MS, Michael J VanWyngarden, BS, Brett M Stevens, PhD, Christophe Langouët-Astrie, MS, Clayton Smith, MD, Brent E Palmer, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Craig T Jordan, PhD, Daniel W Sherbenou, MD PhD

Blood (2018) 132 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2018-99-111394

Published: 2018

Journal Articles

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Courtney L Jones, PhD, Brett M Stevens, PhD, Angelo D'Alessandro, PhD, Julia Reisz, PhD, Rachel Culp-Hill, BS, Travis Nemkov, Shanshan Pei, PhD, Nabilah Khan, Biniam Adane, PhD, Haobin Ye, PhD, Dominik Reinhold, Clayton Smith, MD, James DeGregori, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2018-99-111965

Published: 2018

Journal Articles

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Amanda Winters, MD PhD, Madeline Goosman, Brett M Stevens, PhD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Daniel A Pollyea, MD, Craig T Jordan, PhD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2018-99-110834

Published: 2018

Journal Articles

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Daniel A. Pollyea, MD, Brett M. Stevens, PhD, Amanda Winters, MD PhD, Mohd Minhajuddin, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD FRCPC, Diana Abbott, PhD, Craig T. Jordan, PhD

Blood (2017) 130 (Supplement 1): 181.

https://doi.org/10.1182/blood.V130.Suppl_1.181.181

Published: 2017

NARROW

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

STAT3 Plays a Critical Role in Mitochondrial Function and Survival of Primary AML Cells

Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality

Subversion of Systemic Glucose Metabolism As a Mechanism to Support the Growth of Leukemia Cells

PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia

Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Cysteine and Cystine Depletion Targets Leukemia Stem Cells

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only